IgG-Binding Peptide for Specific Purification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for purifying human IgG antibodies, such as those using protein A columns, face challenges like contamination, high costs due to the need for high purification of protein A, and lack of specificity, which limits their industrial application.

Innovation Solution

A human IgG-binding peptide with a specific amino acid sequence, capable of forming a disulfide bond, is developed for selective binding to human IgG, allowing for its purification and analysis, potentially replacing traditional protein A columns.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If protein A columns are used for IgG purification, then purification efficiency is improved, but contamination with protein A and endotoxin occurs, increasing costs and reducing safety

Engineering Contradiction:
Improvepurification efficiencyVSAvoidprotein A and endotoxin contamination
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The invention extracts only the essential binding function from protein A by identifying and synthesizing a minimal peptide sequence (GPDCAYHRGELVWCTFH) that retains IgG binding capability while eliminating the harmful protein components and endotoxin contamination risks

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention creates a simplified copy of protein A's binding function using a small peptide sequence that mimics the key interaction interface, achieving the desired purification function without the complexity and contamination risks of the full protein

Inventive Principle:
Principle #26Copying

2Reliability

If protein A is highly purified to prevent contamination, then safety is improved, but cost increases due to additional purification steps

Engineering Contradiction:
ImprovesafetyVSAvoidmanufacturing cost
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The invention replaces the expensive, reusable protein A column that requires extensive purification and maintenance with a disposable peptide-based affinity medium that is inherently pure and does not require re-purification between uses

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Manufacturing precision

If protein A columns are used for IgG purification, then purification capability is improved, but specificity decreases due to binding of multiple immunoglobulin classes

Engineering Contradiction:
Improvepurification capabilityVSAvoidbinding specificity
Core Design Contradiction:
Manufacturing precisionVSMeasurement precision

Solution Approach 1:

The invention modifies the binding interface to have localized specificity by designing the peptide sequence to recognize unique structural features of human IgG, thereby achieving high specificity for the target molecule while maintaining strong binding capability

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide demonstrates high specificity for human IgG over other immunoglobulins, enabling efficient and cost-effective purification and analysis, addressing the limitations of existing methods.

Implementation Method 1

a peptide being capable of binding to human IgG, which consists of an amino acid sequence of GPDCAYHRGELVWCTFH

Methodology Applied
Scientific EffectMolecular recognition:

Implementation Method 2

the peptide has a disulfide bond formed between two cysteine (C) residues

Methodology Applied
Scientific EffectDisulfide bond formation: Chemical Bonding

Data Source

PatentEP2749646B1IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
Publication Date: 2018.03.21 KAGOSHIMA UNIV
  • EP2749646B1 patent drawingFigure 1
  • EP2749646B1 patent drawingFigure 2(A)~2(B)
  • EP2749646B1 patent drawingFigure 3

AI summary

Provided is a peptide that specifically or selectively binds to human IgG. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human IgG, wherein the amino acid sequence is represented by formula I: (X1-3)-C-(X2)-H-R-G-(Xaal)-L-V-W-C-(X1-3), wherein, X each independently represents any amino acid residue except cysteine, C represents a cysteine residue, H represents a histidine residue, R represents an arginine residue, G represents a glycine residue, Xaa1 represents a glutamic acid residue or an asparagine residue, L represents a leucine residue, V represents a valine residue, and W represents a tryptophan residue.